Trade Summary

5 days ago, Bredt David, serving as Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 8,500 shares at $29.02 per share, for a total transaction value of $246,655.00. Following this transaction, Bredt David now holds 393,075 shares of RAPP.

This sale represents a 2.00% decrease in Bredt David's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, February 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 19, 2026, 2 days after the trade was made.

Rapport Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.